These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. Zhang G; Wooddell CI; Hegge JO; Griffin JB; Huss T; Braun S; Wolff JA Hum Gene Ther; 2010 Feb; 21(2):221-37. PubMed ID: 19788386 [TBL] [Abstract][Full Text] [Related]
3. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583 [TBL] [Abstract][Full Text] [Related]
4. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? Wells DJ; Wells KE Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S11-22. PubMed ID: 12206790 [TBL] [Abstract][Full Text] [Related]
5. Forced myofiber regeneration promotes dystrophin gene transfer and improved muscle function despite advanced disease in old dystrophic mice. Guibinga GH; Ebihara S; Nalbantoglu J; Holland P; Karpati G; Petrof BJ Mol Ther; 2001 Nov; 4(5):499-507. PubMed ID: 11708887 [TBL] [Abstract][Full Text] [Related]
6. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Jarmin S; Kymalainen H; Popplewell L; Dickson G Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293 [TBL] [Abstract][Full Text] [Related]
7. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034 [TBL] [Abstract][Full Text] [Related]
9. Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle. Kapsa RM; Wong SH; Quigley AF Methods Mol Biol; 2008; 423():405-19. PubMed ID: 18370218 [TBL] [Abstract][Full Text] [Related]
11. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713 [TBL] [Abstract][Full Text] [Related]
12. Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Petrof BJ; Acsadi G; Jani A; Massie B; Bourdon J; Matusiewicz N; Yang L; Lochmüller H; Karpati G Am J Respir Cell Mol Biol; 1995 Nov; 13(5):508-17. PubMed ID: 7576685 [TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Wang B; Li J; Xiao X Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13714-9. PubMed ID: 11095710 [TBL] [Abstract][Full Text] [Related]
14. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034 [TBL] [Abstract][Full Text] [Related]
15. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Dudley RW; Lu Y; Gilbert R; Matecki S; Nalbantoglu J; Petrof BJ; Karpati G Hum Gene Ther; 2004 Feb; 15(2):145-56. PubMed ID: 14975187 [TBL] [Abstract][Full Text] [Related]
16. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Scott JM; Li S; Harper SQ; Welikson R; Bourque D; DelloRusso C; Hauschka SD; Chamberlain JS Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S23-9. PubMed ID: 12206791 [TBL] [Abstract][Full Text] [Related]
17. Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Jiang Z; Schiedner G; van Rooijen N; Liu CC; Kochanek S; Clemens PR Mol Ther; 2004 Oct; 10(4):688-96. PubMed ID: 15451453 [TBL] [Abstract][Full Text] [Related]
18. In utero delivery of oligodeoxynucleotides for gene correction. Cai L; Koppanati BM; Bertoni C; Clemens PR Methods Mol Biol; 2014; 1114():399-411. PubMed ID: 24557918 [TBL] [Abstract][Full Text] [Related]